p14ARF/CDKN2A Antibody

Product Specs
Itemp14ARF/CDKN2A Antibody - BSA Free
CompanyNovus Biologicals, a Bio-Techne Brand
Price $429.00Supplier Page View Company Product Page
Catalog NumberNB200-111
Quantity0.1 ml (also 0.025 ml)
ApplicationsIF/IHC,Flow Cytometry,Immunohistochemistry,Immunoprecipitation,Western Blot,Immunohistochemistry-Paraffin,Immunohistochemistry-Frozen,Knockdown Validated,Immunocytochemistry/ Immunofluorescence
Concentration1.0 mg/ml
Conjugate/TagUnconjugated
FormatPBS
PurityImmunogen affinity purified
Targetp14ARF/CDKN2A
HostRabbit
ReactivityHuman,Mouse
IsotypeIgG
Antibody TypePrimary Antibodies
ImmunogenA synthetic peptide made to a portion of human p14ARF (between residues 50-132). [Swiss-Prot# Q8N726]
ClonalityPolyclonal
NCBI Full Gene Namecyclin dependent kinase inhibitor 2A
NCBI Gene AliasesP16INK4A, P16, CDKN2, MTS1, INK4, MTS-1, P16-INK4A, MLM, P14, CMM2, ARF, P19, P16INK4, P14ARF, TP16, INK4A, P19ARF, CDK4I
Research AreaABC Transporters, Biologically Active Proteins, Cancer, Cell Biology, Cell Cycle and Replication, Chromatin Research, DNA Repair, Hypoxia, MAP Kinase Signaling, Neuroscience, p53 Pathway, Transcription Factors and Regulators, Tumor Suppressors
StorageAliquot and store at -20C or -80C. Avoid freeze-thaw cycles

Specifications/Features

Available conjugates: Unconjugated

Questions and Answers

Can this antibody be used to study the role of p14ARF in cancer biology?

Yes, the p14ARF/CDKN2A antibody has been utilized in various studies to investigate its role in tumor suppression and oncogenic stress responses. For instance, it was referenced in a study that demonstrated the importance of p14ARF in stabilizing p53 under oncogenic stress conditions, highlighting its critical function in tumor suppression ().

Is this antibody effective for immunofluorescence applications?

The p14ARF/CDKN2A antibody has been shown to work in immunofluorescence applications, as indicated by its use in studies examining the localization and function of p14ARF in various cellular contexts, including its interaction with nucleophosmin and its role in regulating p53 stability ().

What species can I use this antibody on?

This antibody is reactive with both human (Homo sapiens) and mouse (Mus musculus) samples, making it suitable for experiments involving these species.

Are there any specific experimental contexts where this antibody has been cited?

Yes, the p14ARF/CDKN2A antibody has been cited in studies focusing on its role in rhabdomyosarcoma and its interaction with other proteins involved in tumorigenesis, such as c-Myc and nucleophosmin, indicating its relevance in cancer research ().

Novus Biologicals, a Bio-Techne Brand

United States: 10771 E Easter Ave

Centennial, Colorado 80112

United States

Phone:
303-730-1950
888-506-6887

Email: novus@novusbio.com

Company Profile

Website: https://www.novusbio.com

(1) Serum amyloid P secreted by bone marrow adipocytes drives skeletal amyloidosisNat AgingSeptember 1, 2025Kumar S, Song K, Wang J, Baghel MS, Zeng Y, Shen K, Zheng J, Crane J, Demehri S, Gao P, et al.1 h and then stained overnight (>8 h) with individual primary antibodies specific to p19ARF (Novus, NB200-111, 1:100), γH2AX (Cell Signaling, 20E3, 1:200), perilipin (Cell Signaling, 9349, 1:200) and perilipin

(2) Combined Endurance and Resistance Exercise Mitigates Age‐Associated Cardiac DysfunctionAdvanced BiologyJune 1, 2025Xiaowei Han, Muhammad Ashraf, Hong Shi, Augustine T. Nkembo, Srinivas M. Tipparaju, Wanling Xuanthen incubated overnight at 4 °C with the primary antibodies: rabbit anti p16INK4a antibody (1:800, NB200–111, Novus Biologicals), mouse anti α-actinin antibody (1:300, A7732, Sigma) and mouse anti cardiac Troponin

(3) p14(ARF) forms meso-scale assemblies upon phase separation with NPM1Nature communicationsNovember 11, 2024Gibbs E, Miao Q, Ferrolino M, Bajpai R, Hassan A, Phillips AH, Pitre A, Kümmerle R, Miller S, Nagy G, et al.monoclonal anti-GAPDH (Santa Cruz, sc-47724) at 1:2500 dilution; and rabbit polyclonal anti-p14Arf (Novus, NB200-111) at 1:2000 dilution. Cell treatments Treatment of doxycycline inducible cells was performed with doxycycline

(4) High WBP5 expression correlates with elevation of HOX genes levels and is associated with inferior survival in patients with acute myeloid leukaemiaScientific reportsFebruary 26, 2020Ward C, Cauchy P, Garcia P, Frampton J, Esteban MA, Volpe G.

(5) Loss of the clock gene PER2 is associated with cancer development and altered expression of important tumor-related genes in oral cancerInternational journal of oncologyJanuary 1, 2018Xiong H, Yang Y, Yang K, Zhao D, Tang H, Ran X.

(6) Novel Roles for Staufen1 in Embryonal and Alveolar Rhabdomyosarcoma via c-myc-dependent and -independent eventsScientific reportsFebruary 17, 2017Crawford Parks TE, Marcellus KA, Langill J, Ravel-Chapuis A, Michaud J, Cowan KN, Côté J, Jasmin BJ.(ab73478, Abcam, Ontario, Canada), anti-c-myc (ab11917, Abcam, Ontario, Canada), anti-p14ARF/CDKN2A (NB200-111, Novus Biologicals, Ontario, Canada), anti-myosin heavy chain (MF20, Developmental Studies Hybridoma

(7) Curcumin homing to the nucleolus: mechanism for initiation of an apoptotic programThe Journal of nutritional biochemistryNovember 1, 2014Ghosh M, Ryan RO.

(8) AKT regulates NPM dependent ARF localization and p53mut stability in tumorsOncotargetAugust 15, 2014Hamilton G, Abraham AG, Morton J, Sampson O, Pefani DE, Khoronenkova S, Grawenda A, Papaspyropoulos A, Jamieson N, McKay C, et al.and anti-p53 (D01 clone) (Ab80645), were purchased from Abcam. Anti-p19ARF (NB-200-174) and anti-p14ARF (NB200-111) were purchased from Novus Biologicals. AntiFLAG (M2) was purchased from Agilent Technologies. Anti-actin

(9) Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growthPloS oneJanuary 1, 2014Williams RT, Barnhill LM, Kuo HH, Lin WD, Batova A, Yu AL, Diccianni MB.Santa Cruz Biotechnology), p16 N-terminus (N-20; 1∶100; Santa Cruz Biotechnology), p14ARF N-terminus (NB200-111; 1∶400; Novus Biologicals), CDK4 (H-22; 1∶400; Santa Cruz Biotechnology), cyclin D1 (CD1.1; 1∶200; Santa

(10) TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylationNature cell biologyMay 6, 2012Chio II, Sasaki M, Ghazarian D, Moreno J, Done S, Ueda T, Inoue S, Chang YL, Chen NJ, Mak TW.

(11) The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasisMolecular cancer research : MCRJuly 1, 2011Muniz VP, Barnes JM, Paliwal S, Zhang X, Tang X, Chen S, Zamba KD, Cullen JJ, Meyerholz DK, Meyers S, et al.

(12) Reactivating the ARF-p53 axis in AML cells by targeting ULFCell cycle (Georgetown, Tex.)August 1, 2010Chen D, Yoon JB, Gu W.

(13) Who chooses the leaders of UN organisations?Lancet (London, England)March 27, 2010Greiner T.

(14) Transcription-independent ARF regulation in oncogenic stress-mediated p53 responsesNatureMarch 25, 2010Chen D, Shan J, Zhu WG, Qin J, Gu W.h, and precleared supernatants were precipitated with rabbit anti-ARF antibody ab-4 (Labvision) or NB200-111 (Novus Biologicals). Immune complexes recovered with protein A/G beads were washed six times with RIPA

(15) Hepatitis B virus X protein via the p38MAPK pathway induces E2F1 release and ATR kinase activation mediating p53 apoptosisThe Journal of biological chemistrySeptember 12, 2008Wang WH, Hullinger RL, Andrisani OM.

(16) The role of NPM, p14arf and MDM2 in precursors of bronchial squamous cell carcinomaThe European respiratory journalSeptember 1, 2008Mascaux C, Bex F, Martin B, Burny A, Haller A, Paesmans M, Willard-Gallo K, Ninane V, Sculier JP.

(17) Frequent p16-independent inactivation of p14ARF in human melanomaJournal of the National Cancer InstituteJune 4, 2008Freedberg DE, Rigas SH, Russak J, Gai W, Kaplow M, Osman I, Turner F, Randerson-Moor JA, Houghton A, Busam K, et al.

(18) Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissuesCancer researchMarch 1, 2006Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, Kaiser S, Aronow BJ, Frahm S, Kluwe L, et al.

(19) N-terminal polyubiquitination and degradation of the Arf tumor suppressorGenes & developmentAugust 1, 2004Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ.

(20) p14ARF expression increases dihydrofolate reductase degradation and paradoxically results in resistance to folate antagonists in cells with nonfunctional p53Cancer researchJune 15, 2004Magro PG, Russo AJ, Li WW, Banerjee D, Bertino JR.

Be the First to Write a Review!